Drug intelligence / Profile preview

APM-176

Development stage: Unknown
Lead developer: Ariel Precision Medicine
Modality: Small Molecules

Overview

APM-176 is a phase 2 ready small molecule drug developed by Ariel Precision Medicine. It is positioned to be the first treatment for pancreatitis, a disease with significant unmet medical need and currently no approved therapeutics. APM-176 belongs to a class of compounds that target defective proteins implicated in pancreatitis and related pancreatic disorders. Mechanistically, it acts as a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, enhancing the function of both mutated and wild-type CFTR. This mechanism makes it relevant for CFTR-mediated chronic conditions such as chronic rhinosinusitis (CRS), pancreatitis, bronchiectasis, and biliary diseases[1][3][10].

Targets

CFTR (Cystic fibrosis transmembrane conductance regulator)

Beyond the preview

Go deeper on APM-176.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APM-176.

Explore the full profile